Assuntos
Molsidomina/administração & dosagem , Infarto do Miocárdio/tratamento farmacológico , Idoso , Idoso de 80 Anos ou mais , Relação Dose-Resposta a Droga , Esquema de Medicação , Teste de Esforço/efeitos dos fármacos , Feminino , Hemodinâmica/efeitos dos fármacos , Humanos , Infusões Intravenosas , Masculino , Pessoa de Meia-Idade , Molsidomina/efeitos adversosRESUMO
The effect of molsidomine on hemodynamic properties was studied in 10 patients with chronic congestive heart failure in New York Heart Association functional classes III and IV. Ten patients with the same degree of heart failure served as control subjects. All patients were receiving standard therapy with digitalis and diuretics. Administration of a single dose of 4 mg of molsidomine orally in the initial phase resulted in significant decreases of pulmonary artery pressure, pulmonary capillary pressure, and right atrial pressure at rest and during exercise (p less than 0.01 and p less than 0.01, respectively). After long-term oral treatment with 4 mg of molsidomine three times daily over a period of 3 weeks, single dose administration of 4 mg of molsidomine orally again caused significant decreases of pulmonary artery, pulmonary capillary, and right atrial pressure at rest and during exercise (range p less than 0.01 to p less than 0.02). Cardiac output, heart rate, systemic arterial pressure, pulmonary artery resistance, and systemic arterial resistance were essentially unchanged.
Assuntos
Insuficiência Cardíaca/tratamento farmacológico , Hemodinâmica/efeitos dos fármacos , Oxidiazóis/uso terapêutico , Sidnonas/uso terapêutico , Vasodilatadores/uso terapêutico , Pressão Sanguínea/efeitos dos fármacos , Débito Cardíaco/efeitos dos fármacos , Ensaios Clínicos como Assunto , Teste de Esforço , Feminino , Insuficiência Cardíaca/fisiopatologia , Humanos , Masculino , Pessoa de Meia-Idade , Molsidomina , Artéria Pulmonar/fisiopatologia , Sidnonas/farmacologia , Resistência Vascular/efeitos dos fármacos , Vasodilatadores/farmacologiaRESUMO
Pimozide, a specific blocker of dopamine receptors, was administered orally to 10 diabetics for 2 days before an arginine-hydrochloride infusion. In 8 healthy volunteers and 20 diabetics exercise tests on a bicycle ergometer were performed with a load of 100 Watts and 50 Watts respectively without or after a single dose of pimozide 30 min before the test. In 4 male diabetics day profiles of growth hormone (GH) were estimated without and during treatment with pimozide for 4 days. The arginine and exercise induced GH release was found to be significantly lowered by pimozide, whereas the marked spontaneous fluctuations in the diabetics were even enhanced by pimozide. These data support the concept of the involvement of dopaminergic stimulation in the response of GH to arginine and exercise. The spontaneous fluctuations of GH, however, seem to be regulated by other neuroendocrine mechanisms.
